{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-266973","form_type":"8-K","ticker":"CTKB","cik":"0001831915","company_name":"Cytek Biosciences, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.690773+00:00","generated_at":"2026-05-17T00:23:58.203139+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cytek Q3 2025 net loss $5.5M; adjusted EBITDA $2.5M; revenue +2% to $52.3M","bullets":["Total revenue $52.3M, +2% YoY; installed base 3,456 instruments (+161 units in Q3).","GAAP net loss $5.5M vs net income $0.9M in Q3 2024; GAAP gross margin 53% vs 56%.","Adjusted EBITDA $2.5M vs $7.6M in prior year; ex-investment income $0.5M vs $5.7M.","Recurring revenue up 19% YoY; biopharma/CRO revenue up 14% YoY.","FY2025 revenue guidance reaffirmed $196M-$205M (-2% to +2% growth)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-266973","json":"https://secwatch.observer/filing/0001193125-25-266973.json","markdown":"https://secwatch.observer/filing/0001193125-25-266973.md","text":"https://secwatch.observer/filing/0001193125-25-266973.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831915/000119312525266973/0001193125-25-266973-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831915/000119312525266973/d161249d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:23:58.203139+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}